Patents by Inventor Bruce M. Baron

Bruce M. Baron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gap junction permeability assay
    Publication number: 20040126817
    Abstract: The present invention is a gap junction assay method and provides methods for both characterizing connexins and for identifying compounds that affect gap junctions function.
    Type: Application
    Filed: August 6, 2003
    Publication date: July 1, 2004
    Inventors: Ann J. Barbier, Bruce M. Baron
  • NMDA (n-methyl-d-aspartate) antagonists
    Patent number: 5922752
    Abstract: The present invention is new excitatory amino acid antagonists (herein referred to as compounds of formula (1)): below: ##STR1## These new antagonists are useful as NMDA (N-methyl-D-aspartate) antagonists.
    Type: Grant
    Filed: September 30, 1997
    Date of Patent: July 13, 1999
    Assignee: Hoechst Marion Roussell, Inc.
    Inventors: Boyd L. Harrison, Raymond S. Gross, Bruce M. Baron
  • 3-aminoindolyl derivatives
    Patent number: 5703107
    Abstract: The present invention is directed to a new class of 3-amido and 3-sulfamido-indolyl NMDA antagonists and their use in the treatment of a number of disease states.
    Type: Grant
    Filed: November 6, 1995
    Date of Patent: December 30, 1997
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Francesco G. Salituro, Bruce M. Baron
  • 3-amidoindolyl derivatives
    Patent number: 5675018
    Abstract: The present invention is directed to a new class of 3-amido and 3-sulfamido-indolyl NMDA antagonists and their use in the treatment of a number of disease states.
    Type: Grant
    Filed: November 6, 1995
    Date of Patent: October 7, 1997
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Francesco G. Salituro, Bruce M. Baron
  • NMDA antagonists
    Patent number: 5606063
    Abstract: The present invention is directed to a new class of 4-sulfanimide-quinoline derivatives and to their use as NMDA antagonists.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: February 25, 1997
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Boyd L. Harrison, Bruce M. Baron, David M. Stemerick, Ian A. McDonald
  • 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
    Patent number: 5519048
    Abstract: The present invention is new 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof. These new 3-indolyl-3-yl-prpopenoic acid derivatives are useful as NMDA antagonist.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: May 21, 1996
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Francesco G. Salituro, Bruce M. Baron, Boyd L. Harrison, Philip L. Nyce
  • NMDA antagonists
    Patent number: 5500419
    Abstract: The present invention is directed to a new neuroprotective agent. The agent is R-4-oxo-5-phosphononorvaline. This agent is useful in the treatment of ischemic and hypoxic conditions such as stroke.
    Type: Grant
    Filed: December 20, 1994
    Date of Patent: March 19, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Jeffrey P. Whitten, Bruce M. Baron
  • 3-amidoindolyl derivative
    Patent number: 5491153
    Abstract: The present invention is directed to a new class of 3-amido and 3-sulfamido-indolyl NMDA antagonists and their use in the treatment of a number of disease states.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: February 13, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Francesco G. Salituro, Bruce M. Baron
  • Potentation of NMDA antagonists
    Patent number: 5489579
    Abstract: The present invention is directed to a method for poteniating the therapeutic effects of selected NMDA antagonists.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: February 6, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Ian A. McDonald, Bruce M. Baron
  • NMDA antagonists
    Patent number: 5470870
    Abstract: The present invention is directed to a class of 4,6-disubstituted tryptophan derivatives, 4,6-disubstituted kynurenines, their use as NMDA antagonists and to pharmaceutical compositions containing these compounds.
    Type: Grant
    Filed: June 17, 1994
    Date of Patent: November 28, 1995
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Ian A. McDonald, Francesco G. Salituro, Robert Schwarcz, Bruce M. Baron
  • Potentiation of NMDA antagonists
    Patent number: 5441963
    Abstract: The present invention is directed to a composition and method for poteniating the therapeutic effects of a class of known NMDA antagonists.
    Type: Grant
    Filed: December 7, 1992
    Date of Patent: August 15, 1995
    Assignee: Merrell Dow Pharmaceuticals
    Inventors: Ian A. McDonald, Bruce M. Baron
  • Arylalkoxyphenoxy-imidazoline compounds
    Patent number: 5407954
    Abstract: The present invention is directed to a new class of arylalkoxyphenoxy-imidazoline compounds and their use for the treatment of depression, anxiety, hypertension, and migraine headaches.
    Type: Grant
    Filed: February 9, 1994
    Date of Patent: April 18, 1995
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Jules Freedman, Bruce M. Baron, Mark W. Dudley
  • NMDA antagonists
    Patent number: 5360814
    Abstract: The present invention is directed to a class of 4,6-disubstituted tryptophan derivatives, 4,6-disubstituted kynurenines, their use as NMDA antagonists and to pharmaceutical compositions containing these compounds.
    Type: Grant
    Filed: January 25, 1994
    Date of Patent: November 1, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Ian A. McDonald, Francesco G. Salituro, Robert Schwarcz, Bruce M. Baron
  • R-4-oxo-5 phosphononorvaline used as NMDA antagonists
    Patent number: 5326756
    Abstract: The present invention is directed to a new class of beta-ketone, beta oxime and beta hydrazine phosphonate NMDA antagonists.
    Type: Grant
    Filed: July 20, 1992
    Date of Patent: July 5, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Jeffrey P. Whitten, Bruce M. Baron
  • Potentiation of NMDA antagonists
    Patent number: 5318985
    Abstract: The present invention is directed to a method for poteniating the therapeutic effects of selected NMDA antagonists.
    Type: Grant
    Filed: December 20, 1991
    Date of Patent: June 7, 1994
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Ian A. McDonald, Bruce M. Baron
  • Arylalkoxyphenoxy-imidazoline compounds
    Patent number: 5216008
    Abstract: The present invention is directed to a new class of arylalkoxyphenoxy-imidazoline compounds and their use for the treatment of depression, anxiety, hypertension, and migraine headaches.
    Type: Grant
    Filed: February 6, 1992
    Date of Patent: June 1, 1993
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Jules Freedman, Bruce M. Baron, Mark W. Dudley
  • 3-amidoindolyl derivatives and pharmaceutical compositions thereof
    Patent number: 5189054
    Abstract: The present invention is directed to a new class of 3-amido and 3-sulfamido-indolyl NMDA antagonists and their use in the treatment of a number of disease states.
    Type: Grant
    Filed: November 12, 1991
    Date of Patent: February 23, 1993
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Francesco G. Salituro, Bruce M. Baron
  • Excitatory amino acid antagonists which are certain thienopyridives
    Patent number: 5112821
    Abstract: The present invention is directed to a new class of excitatory amino acid antagonists.
    Type: Grant
    Filed: February 14, 1991
    Date of Patent: May 12, 1992
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Boyd L. Harrison, Bruce M. Baron
  • Excitatory amino acid antagonists, compositions and use
    Patent number: 5106847
    Abstract: The present invention is directed a new group of indole derivatives that are NMDA antagonists.
    Type: Grant
    Filed: August 1, 1991
    Date of Patent: April 21, 1992
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Francesco G. Salituro, Bruce M. Baron
  • NMDA antagonists
    Patent number: 5095009
    Abstract: The present invention is directed to a new class of 4-(oxoalkyl)phosphono, 4(oxime alkyl)phosphono, or 4-(hydrazine alkyl)phosphono, 2-piperazine carboxylic derivatives that are useful as NMDA antagonists
    Type: Grant
    Filed: July 20, 1990
    Date of Patent: March 10, 1992
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Jeffrey P. Whitten, Bruce M. Baron